REG - IXICO plc - Investor Presentation

IXICOAnnouncement

16/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220516:nRSP4465La&default-theme=true

RNS Number : 4465L  IXICO plc  16 May 2022

16 May 2022

IXICO plc

 

("IXICO", the "Company" or the "Group")

 

Half-year results investor presentation

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience today announces the date of
its investor presentation to accompany its half-year results.

 

Investor presentation

 

Giulio Cerroni (CEO) and Grant Nash (CFO) will provide a live presentation
relating to IXICO's half-year results via the Investor Meet Company platform
on 24(th) May 2022 at 4.30pm BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via: https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C01%7Cgrant.nash%40ixico.com%7C86a8f65f64e54e5a461208da2f358636%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C637874204179296486%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=IJDxxHUz1UsRYiT1TwmEN%2F5Aj2jniH7J7WuRz0twcdw%3D&reserved=0)

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORAJMLTMTTBMRT